About us

ホーム>HOME>Corporate Profile>About us

Company Overview

As of March 31,2026

Company name Perseus Proteomics Inc.
Established Feb. 1, 2001
President & CEO Takuya Yokokawa
Head office

3F, A.i.Nihombashi EAST, 30-1 Nihonbashi Hakozakicho, Chuo-ku, Tokyo 103-0015, JAPAN

Google Map
Nagoya Laboratory

302 / 303 / 306 / 314, NALIC, 2-22-8 Chikusa, Chikusa-ku, Nagoya, Aichi 464-0858, JAPAN
*Visit us in Room No. 314.

Google Map
Capital 751million yen
URL https://www.ppmx.com/en/
Listing market Growth Market, Tokyo Stock Exchange
Securities code 4882
Fiscal year April 1 to March 31
Business Drug discovery (development of antibody drugs), antibody research support, antibody and reagent sales
See here for details.
Employees 35
Board members See here for details.
Audit corporation Shisai Audit Corporation

Company History

　 　 　 　 　

Perseus Proteomics Inc. was established in February 2001, aiming to utilize antibodies (Note 1) targeting diagnostics and drug discovery for medical applications. The establishment was based on the protein expression and antibody production technologies developed at the Laboratory for Systems Biology and Medicine (LSBM), Research Center for Advanced Science and Technology, The University of Tokyo.

　
February 2001 Perseus Proteomics Inc. was established in Bunkyo-ku, Tokyo.
October 2002 Began selling antibodies as research reagents.
April 2003 Participated in the Protein Interaction Analysis Nano-Biochip Project of the New Energy and Industrial Technology Development Organization (NEDO).
July 2003 Relocated its head office to Shibuya-ku, Tokyo.
August 2004 Entered into a distribution agreement with R&D Systems Inc. for research reagents and began global sales.
September 2004 Relocated its head office to Meguro-ku, Tokyo.
September 2005 Began selling antibodies targeting all 48 nuclear receptors.
September 2006 Entered into an agreement with Chugai Pharmaceutical Co., Ltd. to transfer the right to obtain patents and other rights related to the anti-glypican 3 antibody PPMX-T001.
September 2008 Launched the PTX3 ELISA Kit as a research reagent.
November 2008 A Phase I clinical trial of the anti-glypican 3 antibody PPMX-T001 began in the United States.
January 2009 Through a third-party allotment of new shares, FUJIFILM Corporation acquired 76.68% of the Company’s shares and became its parent company.
January 2011 Licensed out PPMX-T002, a radioisotope-labeled anti-cadherin 3 antibody (Note 2) , to FUJIFILM Corporation.
December 2014 The anti-transferrin receptor antibody PPMX-T003 was selected as a supported project under the Japan Science and Technology Agency (JST)’s Program on Open Innovation Platform with Enterprises, Research Institute and Academia, Acceleration Type (Drug Discovery).
September 2015 Licensed out PPMX-T004, an antibody-drug conjugate targeting cadherin 3, to FUJIFILM Corporation.
January 2016 A Phase I clinical trial of PPMX-T002, a radioisotope-labeled anti-cadherin 3 antibody, began in the United States.
March 2018 Following a third-party allotment of new shares, FUJIFILM Corporation’s shareholding in the Company decreased to 48.62%, making FUJIFILM Corporation an “other associated company” of the Company.
January 2019 Opened the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, to maintain and further develop its phage display technology and to promote research and development of antibody drugs.
November 2019 The first in-house clinical trial, a Phase I clinical trial of the anti-transferrin receptor antibody PPMX-T003 for polycythemia vera, began in Japan.
April 2020 A Phase I clinical trial of PPMX-T002, a radioisotope-labeled anti-cadherin 3 antibody anticancer drug, began in Japan.
June 2021 Listed on the Mothers Market of the Tokyo Stock Exchange.
March 2022
Research and development of PPMX-T003 for aggressive NK-cell leukemia (ANKL) was selected as a project under AMED’s Practical Application Support Program before being designated as Orphan Drug, under the Drug Discovery Support Promotion Project, in FY2022.
March 2022 Terminated license agreements with FUJIFILM Corporation for PPMX-T002 and PPMX-T004.
April 2022 Following the Tokyo Stock Exchange’s market restructuring, the Company transitioned from the Mothers Market to the Growth Market.
September 2022 FUJIFILM Corporation ceased to be an “other associated company” of the Company.
March 2023 A clinical trial notification for an investigator-initiated Phase I/II clinical trial of PPMX-T003 for ANKL was submitted and approved.
July 2023 Relocated its head office to Chuo-ku, Tokyo.
February 2025 Research and development of PPMX-T003 for ANKL was selected as a project under AMED’s Practical Application Support Program before being designated as Orphan Drug, under the Drug Discovery Support Promotion Project, in FY2025.
May 2025 Launched its “VHH Antibody Library-Based Screening and Production” service as part of its antibody research support offerings.

Note:
1.Antibody: An antibody is a protein that specifically binds to a particular antigen, a substance that triggers an immune response. This specific binding ability is used in molecularly targeted drugs for the diagnosis and treatment of cancer, infectious diseases, and other conditions.
2.Radioisotope: Also called RI. Isotopes that emit radiation (isotopes are defined as atoms with the same number of protons but different numbers of neutrons).

Origin of Company Name

「“Perseus” is a name of a Greek myth hero while “Proteomics” means research on structures and functions of protein.
Perseus, the hero, is said to have slayed Medusa, a monster who turned everyone who looked at her to stone and have saved Princess Andromeda from a sea monster. This company name represents our mission to fight with diseases (monsters) using antibody technology (Perseus’ weapons) to save patients (Andromeda).